Literature DB >> 21806989

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET.

Lisette Arnaud1, She Chen, Fei Liu, Bin Li, Sabiha Khatoon, Inge Grundke-Iqbal, Khalid Iqbal.   

Abstract

Protein phosphatase-2A (PP2A) activity, which is compromised in Alzheimer disease brain, is regulated by two endogenous inhibitors, one of them being I(2)(PP2A), a 277 amino acid long protein also known as SET. Here we report that both the amino terminal fragment (I(2NTF); aa 1-175) and the carboxy terminal fragment (I(2CTF); aa 176-277) of I(2)(PP2A) inhibit PP2A by binding to its catalytic subunit PP2Ac and cause hyperphosphorylation of tau. The C-terminal acidic region in I(2CTF) and Val 92 in I(2NTF) are essential for their association with PP2Ac and inhibition of the phosphatase activity.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21806989      PMCID： PMC3181127          DOI： 10.1016/j.febslet.2011.07.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  36 in total

1.  The nuclear localization of SET mediated by impalpha3/impbeta attenuates its cytosolic toxicity in neurons.

Authors:  Dianbo Qu; Yi Zhang; Jing Ma; Ke Guo; Rong Li; Yijun Yin; Xinmin Cao; David S Park
Journal:  J Neurochem       Date:  2007-07-02       Impact factor: 5.372

2.  Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A.

Authors:  Xin-Wen Zhou; Jan-Ake Gustafsson; Heikki Tanila; Cecilia Bjorkdahl; Rong Liu; Bengt Winblad; Jin-Jing Pei
Journal:  Neurobiol Dis       Date:  2008-07-23       Impact factor: 5.996

3.  Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.

Authors:  Alejandra del C Alonso; Bin Li; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

4.  The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment.

Authors:  Xiaochuan Wang; Julie Blanchard; Erik Kohlbrenner; Nathalie Clement; R Michael Linden; Aurelian Radu; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  FASEB J       Date:  2010-07-22       Impact factor: 5.191

5.  Activation of glycogen synthase kinase-3 inhibits protein phosphatase-2A and the underlying mechanisms.

Authors:  Gong-Ping Liu; Yao Zhang; Xiu-Qing Yao; Chang-E Zhang; Jiang Fang; Qun Wang; Jian-Zhi Wang
Journal:  Neurobiol Aging       Date:  2007-04-12       Impact factor: 4.673

6.  Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation.

Authors:  Fei Liu; Inge Grundke-Iqbal; Khalid Iqbal; Cheng-Xin Gong
Journal:  Eur J Neurosci       Date:  2005-10       Impact factor: 3.386

Review 7.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

8.  PAT1 induces cell death signal and SET mislocalization into the cytoplasm by increasing APP/APLP2 at the cell surface.

Authors:  Stéphanie Briand; Patricia Facchinetti; Christine Clamagirand; Alexandra Madeira; Jean-Michel Pommet; Sanjay W Pimplikar; Bernadette Allinquant
Journal:  Neurobiol Aging       Date:  2009-06-30       Impact factor: 4.673

9.  Neuroprotective actions of PIKE-L by inhibition of SET proteolytic degradation by asparagine endopeptidase.

Authors:  Zhixue Liu; Sung-Wuk Jang; Xia Liu; Dongmei Cheng; Junmin Peng; Manuel Yepes; Xiao-jiang Li; Steve Matthews; Colin Watts; Masahide Asano; Ikuko Hara-Nishimura; Hongbo R Luo; Keqiang Ye
Journal:  Mol Cell       Date:  2008-03-28       Impact factor: 17.970

10.  Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology.

Authors:  R Liu; X-W Zhou; H Tanila; C Bjorkdahl; J-Z Wang; Z-Z Guan; Y Cao; J-A Gustafsson; B Winblad; J-J Pei
Journal:  J Cell Mol Med       Date:  2008-01-19       Impact factor: 5.310
View more
  43 in total

1.  Regulation of SET Gene Expression by NFkB.

Authors:  Yi Feng; Xiaoyong Li; Weitao Zhou; Dandan Lou; Daochao Huang; Yanhua Li; Yu Kang; Yan Xiang; Tingyu Li; Weihui Zhou; Weihong Song
Journal:  Mol Neurobiol       Date:  2016-06-28       Impact factor: 5.590

2.  Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.

Authors:  Otto Kauko; Susumu Y Imanishi; Evgeny Kulesskiy; Laxman Yetukuri; Teemu Daniel Laajala; Mukund Sharma; Karolina Pavic; Anna Aakula; Christian Rupp; Mikael Jumppanen; Pekka Haapaniemi; Luyao Ruan; Bhagwan Yadav; Veronika Suni; Taru Varila; Garry L Corthals; Jüri Reimand; Krister Wennerberg; Tero Aittokallio; Jukka Westermarck
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

Review 3.  Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer.

Authors:  Parthasarathy Seshacharyulu; Poomy Pandey; Kaustubh Datta; Surinder K Batra
Journal:  Cancer Lett       Date:  2013-02-20       Impact factor: 8.679

4.  Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau.

Authors:  Mohammad Arif; Jianshe Wei; Qi Zhang; Fei Liu; Gustavo Basurto-Islas; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  J Biol Chem       Date:  2014-08-15       Impact factor: 5.157

5.  Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.

Authors:  R Pippa; A Dominguez; D J Christensen; I Moreno-Miralles; M J Blanco-Prieto; M P Vitek; M D Odero
Journal:  Leukemia       Date:  2014-04-30       Impact factor: 11.528

Review 6.  Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Biochem Pharmacol       Date:  2014-01-10       Impact factor: 5.858

7.  Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.

Authors:  M-H Hung; Y-L Chen; P-Y Chu; C-T Shih; H-C Yu; W-T Tai; C-W Shiau; K-F Chen
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

8.  Upregulation of SET expression by BACE1 and its implications in Down syndrome.

Authors:  Xiaozhu Zhang; Yili Wu; Xiaoling Duan; Wei Chen; Haiyan Zou; Mingming Zhang; Shuting Zhang; Fang Cai; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-06-17       Impact factor: 5.590

9.  Therapeutic benefits of a component of coffee in a rat model of Alzheimer's disease.

Authors:  Gustavo Basurto-Islas; Julie Blanchard; Yunn Chyn Tung; Jose R Fernandez; Michael Voronkov; Maxwell Stock; Sherry Zhang; Jeffry B Stock; Khalid Iqbal
Journal:  Neurobiol Aging       Date:  2014-06-17       Impact factor: 4.673

10.  Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice.

Authors:  Gong-Ping Liu; Wei Wei; Xin Zhou; Hai-Rong Shi; Xing-Hua Liu; Gao-Shang Chai; Xiu-Qing Yao; Jia-Yu Zhang; Cai-Xia Peng; Juan Hu; Xia-Chun Li; Qun Wang; Jian-Zhi Wang
Journal:  Mol Ther       Date:  2013-08-07       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.